Ustekinumab (AUUB) manufacturers & suppliers

Ustekinumab (Auub)

Form: Injectable solution (subcutaneous administration)

Strength: 45 mg & 90 mg

Reference Brands: Stelara(US & EU); Wezlana (ustekinumab-auub) is a biosimilar of Stelara

Category: Biosimilars

Ustekinumab (AUUB) is regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality compliant with GMP and MDR standards. In the US, FDA approval involves rigorous clinical validation, safety assessments, and GMP compliance. In the EU, CE marking certifies conformity with MDR regulations. The product undergoes validation, stability testing, and audits, with comprehensive documentation including safety profiles, clinical data, and manufacturing practices. For licensing procedures, approved dossiers, and latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to safe, effective biologic therapies for psoriasis, psoriatic arthritis, and Crohn's disease worldwide, supporting healthcare and patient management effectively.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Insulin‑Aspart‑Szjj

Strength: 100 units/mL

Form: SQ Injection

Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.

View Details
Eculizumab‑Aeeb

Strength: 300 mg/20 mL (IV infusion),

Form: Injection for intravenous infusion

Reference Brands: Soliris, Bkemv- Biosimilar of Soliris, Epysqli- Biosimilar of Soliris

View Details
Omalizumab‑Igec

Strength: 75 mg/0.5 mL and 150 mg/mL

Form: Pre filled syringe

Reference Brands: Xolair, Omlyclo - a Biosimilar to Xolair

View Details
Tocilizumab-Bavi

Strength: 80 mg/4ml

Form: Intravenous infusion

Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.